References
- Provencio M, Cerdeira S, Sánchez A, et al. Rapid-infusion rituximab in lymphoma treatment. Ann Oncol 2006; 17: 1027–1028
- Toma M B, Medina P J. Update on targeted therapy. Focus on monoclonal antibodies. J Pharm Prac 2008; 21: 4–16
- Klocke F J, Baird M G, Lorell B H, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac radionuclide Imaging). Circulation 2003; 108: 1404–1418
- Von Hoff D D, Layard M, Basa P. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979; 91: 701
- Siano M, Lerch E, Negretti L, et al. A phase I-II study to determine the maximum tolerated infusion rate of rituximab with special emphasis on monitoring the effect of rituximab on cardiac function. Clin Cancer Res 2008; 14: 7935–7939
- Panjrath G S, Jain D. Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging. J Nucl Cardiol 2006; 13: 415–426
- Singal P K, Lliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339: 900–905
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
- Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin lymphoma. Ann Oncol 2003; 14: 277–281
- Kilickap S, Yavuz B, Aksoy S, et al. Addition of rituximab to CHOP does not increase the risk of cardiotoxicity in patients with non-Hodgkin lymphoma. Med Oncol 2008; 25: 437–442
- Elbl L, Vasova I, Tomaskova I, et al. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin lymphoma. Neoplasma 2006; 53: 174–181